Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Talazoparib Versus Chemotherapy in Patients With Germline BRCA1/2-Mutated HER2-Negative Advanced Breast Cancer: Final Overall Survival Results From the EMBRACA TrialAnn. Oncol 2020 Aug 20;[EPub Ahead of Print], JK Litton, SA Hurvitz, LA Mina, HS Rugo, KH Lee, A Gonçalves, S Diab, N Woodward, A Goodwin, R Yerushalmi, H Roché, YH Im, W Eiermann, RGW Quek, T Usari, S Lanzalone, A Czibere, JL Blum, M Martin, J Ettl
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.